Fenofibrate Plus Statin and ASCVD Risk by Triglyceride-Rich Lipoprotein Cholesterol in 70,000 Patients - PubMed
6 hours ago
- #Fenofibrate
- #ASCVD Risk
- #TRL-C
- Fenofibrate plus statin therapy is associated with a 24% lower risk of atherosclerotic cardiovascular disease (ASCVD) in individuals with elevated triglyceride-rich lipoprotein cholesterol (TRL-C ≥26 mg/dL).
- The benefit was most pronounced in the highest TRL-C quartile, with a significant interaction, and no significant risk reduction was seen in those with TRL-C below the median.
- Significant ASCVD risk reduction was also observed in individuals with non-HDL cholesterol ≥140 mg/dL, particularly in the 140–172 mg/dL and 172–199 mg/dL ranges.
- The study analyzed 67,662 statin-treated adults without baseline ASCVD from the Korean National Health Insurance Service cohort over a mean follow-up of 87 months.
- Findings suggest TRL-C can help identify statin-treated patients who may derive greater cardiovascular benefit from added fenofibrate therapy.